TNF blockade therapy of RA patients with a humanized antibody (Enbrel) that specifically blocks TNF activity strikingly decreased miR-182 expression levels in CD14 (+) PBMCs after one or two month-treatment (Fig. 7c left panel). This evidence concerns the gene CD14 and rheumatoid arthritis.